HilleVax’s (HLVX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of HilleVax (NASDAQ:HLVX) in a research note released on Tuesday morning, Marketbeat.com reports. The firm currently has a $2.00 price objective on the stock, down from their prior price objective of $28.00. HC Wainwright also issued estimates for HilleVax’s Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($2.27) EPS, FY2025 earnings at ($1.41) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at ($1.27) EPS and FY2028 earnings at ($0.76) EPS.

Several other brokerages have also commented on HLVX. JPMorgan Chase & Co. restated a neutral rating and issued a $5.00 price objective (down from $24.00) on shares of HilleVax in a report on Monday. Guggenheim downgraded shares of HilleVax from a buy rating to a neutral rating in a research note on Monday. Six analysts have rated the stock with a hold rating, According to data from MarketBeat.com, HilleVax has an average rating of Hold and an average price target of $9.20.

HilleVax Stock Performance

NASDAQ HLVX opened at $1.67 on Tuesday. The company has a 50-day simple moving average of $12.80 and a two-hundred day simple moving average of $14.50. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.11. HilleVax has a 12-month low of $1.55 and a 12-month high of $20.22. The firm has a market cap of $83.03 million, a price-to-earnings ratio of -0.51 and a beta of 0.78.

HilleVax (NASDAQ:HLVX) last posted its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). On average, equities analysts forecast that HilleVax will post -3.14 EPS for the current year.

Insider Buying and Selling at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total transaction of $88,380.00. Following the completion of the transaction, the director now owns 764,878 shares of the company’s stock, valued at $11,266,652.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 12,898 shares of company stock valued at $193,766. Corporate insiders own 71.10% of the company’s stock.

Hedge Funds Weigh In On HilleVax

Hedge funds have recently added to or reduced their stakes in the company. Catalys Pacific LLC purchased a new position in HilleVax in the 4th quarter worth approximately $21,009,000. Adage Capital Partners GP L.L.C. purchased a new stake in HilleVax during the 3rd quarter valued at $2,374,000. Franklin Resources Inc. raised its stake in HilleVax by 4.1% during the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after buying an additional 71,938 shares during the last quarter. abrdn plc purchased a new stake in HilleVax during the 4th quarter valued at $433,000. Finally, SG Americas Securities LLC purchased a new stake in HilleVax during the 4th quarter valued at $139,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.